Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
BIIB Stock Forecast 2026-2027
$185.95
Current Price
$27.29B
Market Cap
Buy 18
Hold 17
Sell 1
Wall St Analyst Ratings
Distance to BIIB Price Targets
+47.9%
To High Target of $275.00
+9.4%
To Median Target of $203.50
-19.3%
To Low Target of $150.00
BIIB Price Momentum
+3.0%
1 Week Change
+2.5%
1 Month Change
+56.4%
1 Year Change
+5.7%
Year-to-Date Change
-8.1%
From 52W High of $202.41
+61.3%
From 52W Low of $115.25
📊 TOP ANALYST CALLS
Did BIIB Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Biogen is one of their latest high-conviction picks.
Latest BIIB Stock Price Targets & Analyst Predictions
Based on our analysis of 50 Wall Street analysts, BIIB has a neutral consensus with a median price target of $203.50 (ranging from $150.00 to $275.00). The overall analyst rating is Buy (7.7/10). Currently trading at $185.95, the median forecast implies a 9.4% upside. This outlook is supported by 18 Buy, 17 Hold, and 1 Sell ratings.
The most optimistic forecast comes from Jay Olson at Oppenheimer, projecting a 47.9% upside. Conversely, the most conservative target is provided by Rajesh Kumar at HSBC, suggesting a 19.3% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
BIIB Analyst Ratings
18
Buy
17
Hold
1
Sell
BIIB Price Target Range
Low
$150.00
Average
$203.50
High
$275.00
Current: $185.95
Latest BIIB Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for BIIB.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 14, 2026 | Piper Sandler | David Amsellem | Overweight | Upgrade | $214.00 |
| Apr 13, 2026 | Citigroup | Geoff Meacham | Neutral | Maintains | $190.00 |
| Apr 13, 2026 | Truist Securities | Srikripa Devarakonda | Hold | Maintains | $189.00 |
| Apr 10, 2026 | Morgan Stanley | Matthew Harrison | Equal-Weight | Maintains | $200.00 |
| Apr 2, 2026 | HC Wainwright & Co. | Andrew S. Fein | Buy | Maintains | $237.00 |
| Apr 1, 2026 | Canaccord Genuity | Sumant Kulkarni | Buy | Maintains | $245.00 |
| Apr 1, 2026 | Oppenheimer | Jay Olson | Outperform | Maintains | $275.00 |
| Mar 17, 2026 | HSBC | Rajesh Kumar | Reduce | Maintains | $150.00 |
| Feb 23, 2026 | Freedom Broker | Hold | Maintains | $N/A | |
| Feb 20, 2026 | Barclays | Emily Field | Equal-Weight | Initiates | $185.00 |
| Feb 10, 2026 | Wedbush | Laura Chico | Neutral | Maintains | $187.00 |
| Feb 9, 2026 | Wedbush | Laura Chico | Neutral | Maintains | $187.00 |
| Feb 9, 2026 | BMO Capital | Evan Seigerman | Market Perform | Maintains | $196.00 |
| Feb 9, 2026 | Guggenheim | Yatin Suneja | Buy | Maintains | $246.00 |
| Feb 9, 2026 | Piper Sandler | David Amsellem | Neutral | Maintains | $177.00 |
| Feb 9, 2026 | HC Wainwright & Co. | Andrew S. Fein | Buy | Maintains | $228.00 |
| Feb 9, 2026 | Truist Securities | Srikripa Devarakonda | Hold | Maintains | $193.00 |
| Feb 9, 2026 | Canaccord Genuity | Sumant Kulkarni | Buy | Maintains | $230.00 |
| Feb 9, 2026 | Wells Fargo | Mohit Bansal | Equal-Weight | Maintains | $200.00 |
| Feb 9, 2026 | JP Morgan | Neutral | Maintains | $N/A |
Biogen Inc. (BIIB) Competitors
The following stocks are similar to Biogen based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Biogen Inc. (BIIB) Financial Data
Biogen Inc. has a market capitalization of $27.29B with a P/E ratio of 20.7x. The company generates $9.89B in trailing twelve-month revenue with a 13.1% profit margin.
Revenue growth is -7.1% quarter-over-quarter, while maintaining an operating margin of +19.6% and return on equity of +7.4%.
Valuation Metrics
Market Cap
$27.29B
Enterprise Value
$28.87B
P/E Ratio
20.7x
PEG Ratio
-0.2x
Price/Sales
2.7x
Growth & Margins
Revenue Growth (YoY)
-7.1%
Gross Margin
+78.3%
Operating Margin
+19.6%
Net Margin
+13.1%
EPS Growth
-7.1%
Financial Health
Cash/Price Ratio
+14.0%
Current Ratio
2.7x
Debt/Equity
36.5x
ROE
+7.4%
ROA
+6.1%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Biogen Inc. (BIIB) Business Model
About Biogen Inc.
What They Do
Develops therapies for neurological diseases.
Business Model
Biogen Inc. generates revenue by discovering, developing, and manufacturing a range of therapies targeted at neurological and neurodegenerative diseases. The company markets and sells its products, including multiple sclerosis treatments and therapies for spinal muscular atrophy and other rare diseases, through specialized healthcare channels across various regions.
Additional Information
Founded in 1978 and headquartered in Cambridge, Massachusetts, Biogen is recognized for its commitment to addressing unmet medical needs in neurology. Its innovative approach focuses on targeting the underlying mechanisms of debilitating conditions, making it a key player in the biopharmaceutical industry.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
7,500
CEO
Mr. Christopher A. Viehbacher
Country
United States
IPO Year
1991
Website
www.biogen.comBiogen Inc. (BIIB) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
BIIB Inks Deal to Acquire Rights to Felzartamab in China, Stock Up
Biogen gains after securing Greater China rights to felzartamab, giving it worldwide control as phase III studies advance in immune diseases.
Apr 21, 2026
By Zacks Equity Research
Analyst Blog
Align Technology's Q1 Earnings on Deck: Here's What to Expect
ALGN's Q1 report looms with revenues seen rising 4.3% and EPS up 6.1%, as Invisalign demand and iTero adoption drive growth trends.
Apr 21, 2026
By Zacks Equity Research
Analyst Blog
Edwards Lifesciences' Q1 Earnings on Deck: Here's What to Expect
EW heads into Q1 earnings with TAVR strength, rising estimates and momentum in mitral and tricuspid therapies shaping expectations.
Apr 20, 2026
By Zacks Equity Research
Analyst Blog
Latest News
Biogen buys China rights to immune disease drug in up to $850 million deal with TJ Biopharma
2 days ago
Quick Summary
Biogen will pay up to $850 million for exclusive rights to an experimental immune disease treatment in Greater China from TJ Biopharma, securing worldwide development and marketing rights.
Why It Matters
Biogen's $850 million acquisition expands its portfolio in a high-growth market, potentially boosting revenue and enhancing its position in the immune disease treatment sector.
Source: Reuters
Market Sentiment:
Positive
Wells Fargo Upgrades Biogen to Overweight: Does the Alzheimer's Story Finally Have a Second Act?
2 days ago
Quick Summary
Wells Fargo upgraded Biogen (NASDAQ:BIIB) to Overweight from Equal Weight, increasing the price target from $200 to $250, signaling positive outlook for the stock.
Why It Matters
Wells Fargo's upgrade of Biogen to Overweight and increased price target signals confidence in the stock's potential for growth, likely attracting more investor interest and driving share prices higher.
Source: 24/7 Wall Street
Market Sentiment:
Positive
Quick Summary
Biogen has secured rights to felzartamab in Greater China, granting worldwide control as phase III studies progress in immune diseases, leading to a rise in its stock value.
Why It Matters
Biogen's acquisition of Greater China rights to felzartamab enhances its market position and potential revenue, especially as phase III studies progress, signaling growth opportunities in immune diseases.
Source: Zacks Investment Research
Market Sentiment:
Positive
Biogen Enters into Agreement with TJ Biopharma for Felzartamab Assets in the Greater China Region
2 days ago
Quick Summary
Biogen Inc. has acquired exclusive rights to felzartamab in Greater China from TJ Biopharma, gaining worldwide rights to the drug, which is in Phase 3 trials for immune-mediated diseases.
Why It Matters
Biogen's acquisition of felzartamab rights enhances its portfolio, potentially boosting revenue from immune-mediated disease treatments, which could positively impact stock performance and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Apellis Pharmaceuticals is being sold to Biogen for $41.00 per share, plus two contingent payments of $2.00 each. An investigation into the deal is ongoing.
Why It Matters
The investigation into Apellis Pharmaceuticals' sale to Biogen may indicate potential legal or valuation issues, affecting shareholder confidence and stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
BIIB, LMT, NOC, MA, and MTD are identified as strong non-tech stocks with competitive advantages, benefiting from defense demand and growth in digital payments.
Why It Matters
The excerpt highlights five stocks with strong competitive advantages, suggesting potential for stable returns amid market fluctuations, appealing to risk-averse investors seeking reliable growth.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About BIIB Stock
What is Biogen Inc.'s (BIIB) stock forecast for 2026?
Based on our analysis of 50 Wall Street analysts, Biogen Inc. (BIIB) has a median price target of $203.50. The highest price target is $275.00 and the lowest is $150.00.
Is BIIB stock a good investment in 2026?
According to current analyst ratings, BIIB has 18 Buy ratings, 17 Hold ratings, and 1 Sell ratings. The stock is currently trading at $185.95. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for BIIB stock?
Wall Street analysts predict BIIB stock could reach $203.50 in the next 12 months. This represents a 9.4% increase from the current price of $185.95. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Biogen Inc.'s business model?
Biogen Inc. generates revenue by discovering, developing, and manufacturing a range of therapies targeted at neurological and neurodegenerative diseases. The company markets and sells its products, including multiple sclerosis treatments and therapies for spinal muscular atrophy and other rare diseases, through specialized healthcare channels across various regions.
What is the highest forecasted price for BIIB Biogen Inc.?
The highest price target for BIIB is $275.00 from Jay Olson at Oppenheimer, which represents a 47.9% increase from the current price of $185.95.
What is the lowest forecasted price for BIIB Biogen Inc.?
The lowest price target for BIIB is $150.00 from Rajesh Kumar at HSBC, which represents a -19.3% decrease from the current price of $185.95.
What is the overall BIIB consensus from analysts for Biogen Inc.?
The overall analyst consensus for BIIB is neutral. Out of 50 Wall Street analysts, 18 rate it as Buy, 17 as Hold, and 1 as Sell, with a median price target of $203.50.
How accurate are BIIB stock price projections?
Stock price projections, including those for Biogen Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 22, 2026 5:29 AM UTC